
Alvotech recruit new CEO from within
pharmafile | August 9, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alvotech, biotech, drugs, pharma, pharmaceutical
Alvotech, a biopharmaceutical company focusing on the development and manufacture of based in Reykjavik, Iceland, has replaced outgoing CEO, Eef Schimmelpennink, with Rasmus Rojkjaer. The company has only existed since 2013, after being spun out of Alvogen, and Rojkjaer has only recently joined the company.
Rojkjaer has been with Alvotech since 2016, and previously performed the role of Chief Operating Officer. Before his time at Alvotech, Rojkjaer had plenty of experience working at Novo Nordisk, as a Senior Director, and as Chairman of the Board at Mylan.
He is tasked with creating a global market leader in biogenerics through the development of high quality and cost-controlled biosimilar products. He will be expected to tap into his experience with Mylan for this project, where he created and led the establishment of its biosimilar strategy. Rojkjaer will also join the executive board at Alvogen.
Robert Wessman, Alvotech’s Chairman and founder, said: “Rasmus has been an integral part of Alvotech‘s management team since joining us in 2016 as Chief Operating Officer, and we are fortunate to have someone with his experience to lead our biosimilar business going forward. The company has achieved many important milestones since its launch in 2013. Now, as Alvotech enters the next phase, Eef will be leaving to take on new ventures. On behalf of the Board and management team, I would like to thank Eef for his contributions to Alvotech.”
Related Content

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






